While comprehensive studies with long-term follow-up on the effect of PCSK9 inhibitors on the clinical course of patients with NAFLD are lacking, preliminary data suggest beneficial effects and indicate that PCSK9 inhibitors may ameliorate NAFLD via different mechanisms [122]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.